A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE(R) (STACCATO(R) Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Trial Profile

A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE(R) (STACCATO(R) Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Loxapine (Primary)
  • Indications Agitation
  • Focus Pharmacokinetics
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 15 Feb 2017 Results published in the Clinical Pharmacokinetics.
    • 21 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Aug 2015 According to Alexza Pharmaceuticals media release, Teva expects to file the clinical study report later in 2015 with the U.S. Food and Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top